Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1-10 of 12 for

  • Results filtered:
  • Study status: Open/Status Unknown
Edit search filters
  1. Turkey Tail Mushroom For Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery

    Scottsdale/Phoenix, AZ

  2. A Study Of Elacestrant Versus Standard Endocrine Therapy In Women And Men With ER+,HER2-, Early Breast Cancer With High Risk Of Recurrence

    Albert Lea, MN, Scottsdale/Phoenix, AZ, Eau Claire, WI, Jacksonville, FL, La Crosse, WI, Mankato, MN, Rochester, MN

  3. Trial Of 225Ac-DOTATATE (RYZ101) Alone And With Pembrolizumab In Subjects With ER+, HER2-negative Unresectable Or Metastatic Breast Cancer Expressing SSTRs (TRACY-1)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  4. Lasofoxifene And Abemaciclib To The Combination Of Fulvestrant And Abemaciclib For Locally Advanced Or Metastatic ER+/HER2− Breast Cancer

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  5. Adaptive Therapy With Capecitabine For Treatment Of Metastatic ER Positive, HER2 Negative Breast Cancer

    Scottsdale/Phoenix, AZ

  6. Saruparib (AZD5305) Plus Camizestrant Or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy Or Plus Camizestrant In HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, Or PALB2m Advanced Breast Cancer

    Jacksonville, FL, Rochester, MN

  7. Evaluating The Addition Of Adjuvant Chemotherapy To Ovarian Function Suppression Plus Endocrine Therapy In Premenopausal Patients With PN0-1, ER-Positive/HER2-Negative Breast Cancer And An Oncotype Recurrence Score Less Than Or Equal To 25

    Scottsdale/Phoenix, AZ, Jacksonville, FL, La Crosse, WI, Mankato, MN, Rochester, MN

  8. Phase Ib Study Of Axatilimab In Combination With Olaparib In BRCA1/2 And PALB2- Associated Metastatic HER2-negative Breast Cancer

    Rochester, MN

  9. 5-strain Probiotic Formulation In Hormone Receptor-positive Breast Cancer Receiving Aromatase Inhibitor To Prevent Bone Loss

    Jacksonville, FL

  10. Study Of The Bria-IMT Regimen And CPI Vs Physicians' Choice In Advanced Metastatic Breast Cancer. (BRIA-ABC)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

.

Mayo Clinic Footer